Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.16), $0.06 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $2.67 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.